DETERMINE precision medicine trial
DETERMINE is the first UK national precision medicine trial in rare cancers
Led by the University of Manchester and sponsored and managed by Cancer Research UK's Centre for Drug Development, DETERMINE is a multi-drug, precision medicine trial for adults, teenagers and children with rare cancers.
It's run in collaboration with the University of Birmingham, the Royal Marsden NHS Foundation Trust and the Christie NHS Foundation Trust. DETERMINE is a trial open in the UK and is expected to recruit until 2027. This trial is exploring whether treatments approved for use in some cancer types can target identifiable genetic alterations in other types. It also provides new treatment options for those who might not have any left.
Drugs which show promising results will be accelerated for Cancer Drug Fund assessment and NHS approval.
How to join DETERMINE
For patients
Taking part in the trial is a personal decision. Speak to your doctor if you're interested in participating.
For clinicians
Learn more about patient eligibility, referrals, practicing sites across the UK and treatment arms.
For partners
Find out about the benefits of becoming a commercial partner, meet our current partners and more.
Meet our investigators
Dr Matthew Krebs
Chief Investigator University of Manchester
Dr Krebs is a medical oncologist with expertise in precision medicine. He is responsible for the medical, scientific and strategic oversight of the DETERMINE platform. He is also the Chief Investigator of the TARGET Precision Medicine program, which is a major route for patent identification for DETERMINE.
Dr Lynley Marshall
Paediatric Lead Royal Marsden Hospital
Dr Marshall is a paediatric oncologist with expertise in drug development. She is responsible for overseeing the medical and scientific aspects of the DETERMINE study with respect to children and young people.
Professor Gary Middleton
Translational Lead University of Birmingham
Professor Middleton is a medical oncologist with expertise in the genomic, transcriptomic and immunological context underlying response to targeted therapy. He is Translational Lead for the DETERMINE study and will coordinate academic research at the Universities of Manchester and Birmingham and the Institute of Cancer Research.
Professor Lucinda Billingham
Statistical Lead University of Birmingham
Professor Billingham is a biostatistician with an interest in cancer research. She is responsible for the design and statistical analysis of the DETERMINE study.
Meet our collaborators
University of Manchester
The DETERMINE trial is led by the University of Manchester.
The Centre for Drug Development
The DETERMINE trial is sponsored and managed by Cancer Research UK's Centre for Drug Development.
University of Birmingham
The DETERMINE trial is run in collaboration with the University of Birmingham.
The Royal Marsden NHS Foundation Trust
The DETERMINE trial is run in collaboration with The Royal Marsden NHS Foundation Trust.
Our participating sites
Adults | Paediatrics, teenagers, young adults | |
|---|---|---|
England | 1. Manchester: Christie Hospital NHS Foundation Trust | 1. London/Surrey: Royal Marsden Hospital |
2. Birmingham: University Hospitals Birmingham NHS Foundation Trust | 2. Bristol: The Bristol Royal Hospital for Children | |
3. Bristol: Haematology and Oncology Centre | 3. Cambridge: Addenbrooke's Hospital | |
4. Cambridge: Addenbrooke's Hospital | 4. Liverpool: Alder Hey Children's Hospital | |
5. Leicester: Leicester Royal Infirmary | 5. London: Great Ormond Street Hospital | |
6. Liverpool: Clatterbridge Cancer Centre NHS Foundation Trust | 6. Manchester: in set up | |
7. London: Guy's Hospital | 7. Newcastle upon Tyne: Great North Children's Hospital | |
8. London: University College London Hospital | 8. Oxford: John Radcliffe Hospital | |
9. Newcastle upon Tyne: Freeman Hospital | 9. Sheffield: Sheffield Children's Hospital | |
10. Oxford: Churchill Hospital | ||
11. Sheffield: Weston Park Hospital | ||
12. Southampton: University Hospital Southampton NHS Foundation Trust | ||
Wales | 13. Cardiff: Velindre Cancer Centre | 10. Cardiff: in set up |
Scotland | 14. Edinburgh: Western General Hospital | 11. Glasgow: The Royal Hospital for Sick Children |
15. Glasgow: The Beatson West of Scotland Cancer Centre | ||
Northern Ireland | 16. Belfast: Health and Social Care Trust | Coming soon |
Other things you may be interested in
Our latest news
Discover more about the DETERMINE precision medicine trial through our latest press releases, articles, awards and network updates.
Experimental cancer medicine centres network (ECMC)
DETERMINE is delivered through the ECMC network, which supports Cancer Research UK, industry, other funders and partners with early phase trials.
PRIME-ROSE
DETERMINE is part of PRIME-ROSE, which aims to broaden patient access to a wider range of innovative precision cancer medicine treatments by connecting similar clinical trials.